Literature DB >> 6783428

Disorder of collagen metabolism in a patient with osteogenesis imperfecta (lethal type): increased degree of hydroxylation of lysine in collagen types I and III.

E Kirsch, T Krieg, K Remberger, H Fendel, P Bruckner, P K Müller.   

Abstract

Types I, II and III collagen were isolated from calvarium, skin and cartilage from a patient with recessive lethal osteogenesis imperfecta. the distribution of the various collagen types was normal in all three tissues. The alpha-chains were purified by molecular sieve and ion-exchange chromatography and were found to differ from the corresponding alpha-chains of age-matched controls only in that the alpha 1(I), alpha 2 and alpha 1(III) chains contained higher amounts of hydroxylysine with proportionally less lysine. alpha 1(II) was normal. The excess hydroxylysine residues were all glycosylated in the case of alpha 1(I) chains, but only partly so for the alpha 2 chains. Similar observations were made with collagen from fetuses at various stages of development. In these fetuses, however, the increase in the degree of hydroxylation of lysine in alpha 1(I), alpha 2 and alpha 1(III) varied with age, being highest in the youngest fetus. Seen in the context of embryonic development, the collagen of the patient would correspond to that of a fetus younger than 18 weeks, and one could speculate that the defect seen in this patient is the result of a disturbed process of maturation of connective tissue.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6783428     DOI: 10.1111/j.1365-2362.1981.tb01763.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  18 in total

1.  Lysyl hydroxylation in collagens from hyperplastic callus and embryonic bones.

Authors:  H W Lehmann; M Bodo; C Frohn; A Nerlich; D Rimek; H Notbohm; P K Müller
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

Review 2.  The role of collagen in bone strength.

Authors:  S Viguet-Carrin; P Garnero; P D Delmas
Journal:  Osteoporos Int       Date:  2005-12-09       Impact factor: 4.507

3.  Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK.

Authors:  P N Tasker; H Macdonald; W D Fraser; D M Reid; S H Ralston; O M E Albagha
Journal:  Osteoporos Int       Date:  2006-05-04       Impact factor: 4.507

4.  Heterogeneity of osteogenesis imperfecta. Biochemical and morphological findings in a case of type III according to Sillence.

Authors:  H Stöss; B F Pontz; H J Pesch; R Ott
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

5.  Biochemical changes in the collagenous matrix of osteoporotic avian bone.

Authors:  L Knott; C C Whitehead; R H Fleming; A J Bailey
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

6.  Analysis of cyanogen bromide peptides of type I collagen from a patient with lethal osteogenesis imperfecta.

Authors:  E Kirsch; R W Glanville; T Krieg; P Müller
Journal:  Biochem J       Date:  1983-06-01       Impact factor: 3.857

7.  Osteogenesis imperfecta: a heterogeneous morphologic phenotype in cultured dermal fibroblasts.

Authors:  A P Boright; G A Lancaster; C R Scriver
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

8.  An unusual pattern of peptide-bound lysine metabolism in collagen from an infant with lethal perinatal osteogenesis imperfecta.

Authors:  O M Petrovic; E J Miller
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Abnormal type I collagen metabolism by cultured fibroblasts in lethal perinatal osteogenesis imperfecta.

Authors:  J F Bateman; T Mascara; D Chan; W G Cole
Journal:  Biochem J       Date:  1984-01-01       Impact factor: 3.857

10.  Osteonectin, bone proteoglycan, and phosphophoryn defects in a form of bovine osteogenesis imperfecta.

Authors:  J D Termine; P G Robey; L W Fisher; H Shimokawa; M A Drum; K M Conn; G R Hawkins; J B Cruz; K G Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.